Julie Rubinstein has served as our President since February 2018. Prior to becoming our President, Julie served as our Chief Business Officer from January 2016 to February 2018, and our head of Corporate and Business Development from April 2011 to January 2016. Prior to joining us, Julie held various worldwide commercial development roles at Pfizer Inc.’s Oncology division, primarily focusing on cancer immunotherapy. She also served in various roles with Johnson & Johnson Services, Inc., including in Europe. Julie currently serves on the Board of Trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York. Julie holds an MBA from Harvard Business School and dual undergraduate degrees from The Wharton School and Annenberg School of Communications at the University of Pennsylvania.